Des-γ-carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma

1 Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial The Lancet Oncology, April 24, 2013

2 Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study The Lancet Oncology, April 24, 2013

3 Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: Results from the HERA Trial Journal of Clinical Oncology, April 25, 2013

4 Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma Annals of Oncology, May 14, 2013

5 Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma Diseases of the Esophagus, April 30, 2013

6 Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States Journal of Clinical Oncology, May 9, 2013

7 Stearoyl-coa desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma Clinical Cancer Research, May 8, 2013

8 Clinical analysis of prophylactic central neck dissection for papillary thyroid carcinoma Clinical and Translational Oncology, April 22, 2013

9 Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial The Lancet Oncology, May 16, 2013

10 Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors Annals of Oncology, May 13, 2013